Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer

Byounghoon Hwang, Kyungsook Han, Seong Wook Lee

Research output: Contribution to journalArticlepeer-review

32 Scopus citations

Abstract

Myasthenia gravis (MG) and its animal model, experimental autoimmune MG (EAMG), are mainly caused by autoantibodies directed against acetylcholine receptors (AChR) located in the postsynaptic muscle membrane. Previously, we isolated an RNA aptamer with 2′-fluoropyrimidines using in vitro selection techniques that acted as an effective decoy against both a rat monoclonal antibody called mAb198, which recognizes the main immunogenic region on the AChR, and a significant fraction of patient autoantibodies with MG. To investigate the therapeutic potential of the RNA, we tested the ability of the RNA aptamer to protect the receptors in vivo from mAb198. Clinical symptoms of EAMG in rats engendered by passive transfer of mAb198 were efficiently inhibited by a truncated RNA aptamer that was modified with polyethylene glycol, but not by control scrambled RNA. Moreover, the loss of AChR in the animals induced by the antibody was also significantly blocked with the modified RNA aptamer. These results suggested that RNA aptamers could be applied for antigen-specific treatment for autoimmune diseases including MG.

Original languageEnglish
Pages (from-to)85-89
Number of pages5
JournalFEBS Letters
Volume548
Issue number1-3
DOIs
StatePublished - 31 Jul 2003

Keywords

  • Acetylcholine receptor
  • Autoantibody
  • Experimental autoimmune myasthenia gravis
  • In vitro selection
  • RNA aptamer

Fingerprint

Dive into the research topics of 'Prevention of passively transferred experimental autoimmune myasthenia gravis by an in vitro selected RNA aptamer'. Together they form a unique fingerprint.

Cite this